Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Alexander, Raufi"'
Autor:
Varun Vijay Prabhu, Sara Morrow, Abed Rahman Kawakibi, Lanlan Zhou, Marie Ralff, Jocelyn Ray, Aakash Jhaveri, Isacco Ferrarini, Young Lee, Cassandra Parker, Yiqun Zhang, Robyn Borsuk, Wen-I Chang, Joshua N. Honeyman, Fabio Tavora, Benedito Carneiro, Alexander Raufi, Kelsey Huntington, Lindsey Carlsen, Anna Louie, Howard Safran, Attila A. Seyhan, Rohinton S. Tarapore, Lee Schalop, Martin Stogniew, Joshua E. Allen, Wolfgang Oster, Wafik S. El-Deiry
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agon
Externí odkaz:
https://doaj.org/article/ab2136215d2b48418947dffdd2998a3e
Autor:
Rimini Breakstone, Khaldoun Almhanna, Alexander Raufi, Rachel E. Beard, Kara-Lynne Leonard, Jennifer Renaud, Michaela Kastura, Sopha Dionson, Roxanne Wood, Ashlee Sturtevant, Thomas Dipetrillo, Adam Olszewski, Howard Safran
Publikováno v:
American journal of clinical oncology. 45(8)
To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC].BrUOG-292 and BrUOG-318 were two co
Autor:
Ujwal Punyamurtula, Shengliang Zhang, Thomas Brown, Arielle De La Cruz, Alexander Raufi, Jillian Strandberg, Lindsey Carlsen, Lanlan Zhou, Wafik El-Deiry
Publikováno v:
Cancer Research. 82:3241-3241
The 50% inhibitory concentration (IC50) is a widely used measure of how effective a given anti-cancer therapeutic is at reducing cancer cell viability in vitro. It is known that IC50 of a given therapeutic agent is dependent on the seeding density of
Publikováno v:
Journal of Clinical Oncology. 40:e16113-e16113
e16113 Background: Diagnosing cholangiocarcinoma (CCA) can be challenging and these tumors are often misclassified as adenocarcinomas of unknown primary (AUP). Accurate identification is critically important to determine the true incidence and to und
Autor:
Michael S. May, Alissa Michel, Tristan Lee, Winston Wong, Jacob K.R. Jamison, David Manrique, Samuel M Pan, Jianhua Hu, Rachael A Safyan, Alexander Raufi, Michael Kluger, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji
Publikováno v:
Journal of Clinical Oncology. 40:608-608
608 Background: Recurrence rates after resection of pancreatic ductal adenocarcinoma (PDA) can be up to 80%. Prior data suggests that initial site of recurrence influences prognosis. This study aims to compare survival of patients (pts) with resected
Autor:
Winston Wong, Jacob K.R. Jamison, Michael S. May, Alissa Michel, Tristan Lee, David Manrique, Alexander Raufi, Samuel M Pan, Rachael A Safyan, David Paul Horowitz, Beth Schrope, Michael Kluger, Lisa A. Kachnic, Jianhua Hu, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji
Publikováno v:
Journal of Clinical Oncology. 40:565-565
565 Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a minority of patients (pts) eligible for curative resection. Currently, systemic treatment options for down-staging pts with borderline resectable or locally advance
Publikováno v:
Translational lung cancer research. 4(5)
The increasing appreciation of oncogenic driver alterations in non-small cell lung cancer (NSCLC) has resulted in a rapid expansion of therapeutic compounds. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations are